Named on 12 rounds in the feed, most often at Series A and in Biotech.
Rounds from 2017-11-06 to 2026-07-15
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
AdvanCell AdvanCell is developing targeted alpha radiotherapies for cancer. | Series D Verified against 4 of 6 sources[ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $315M | 2026-07-15 | [ PART ] |
R1 Therapeutics A biopharmaceutical company focused on developing therapies for kidney disease | Series A Verified against 1 of 7 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $77.5M | 2026-03-17 | [ LEAD ] |
Addition Therapeutics Additiontx sells genetic medicines using their PRINT technology to address severe lifelong diseases in patients. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $100M | 2025-12-17 | [ PART ] |
Solve Therapeutics Novel antibody-drug conjugates (ADCs) for cancer treatment targeted at solid tumors and optimized for payload delivery using proprietary technology. | Funding round Verified against 1 of 4 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $120M | 2025-11-17 | [ PART ] |
Glycomine Glycomine develops replacement therapies for rare genetic diseases, particularly focusing on PMM2-CDG treatments. | Series C Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $115M | 2025-04-16 | [ PART ] |
Atsena Therapeutics Atsena Therapeutics develops gene therapies for inherited retinal diseases, targeting conditions like X-linked retinoschisis and Leber congenital amaurosis. | Series C Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $150M | 2025-04-02 | [ PART ] |
AdvanCell AdvanCell is developing targeted alpha radiotherapies for cancer. | Series C Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $112M | 2025-02-03 | [ LEAD ] |
Timberlyne Therapeutics Timberlyne Therapeutics develops biopharmaceutical therapies for autoimmune diseases. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $180M | 2025-01-09 | [ LEAD ] |
Allotera Therapeutics Allotera Therapeutics develops allogeneic T-cell therapies targeted at treating various types of blood cancers like leukemia and lymphoma. | Series B Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $172M | 2021-07-15 | [ LEAD ] |
Glycomine Glycomine develops replacement therapies for rare genetic diseases, particularly focusing on PMM2-CDG treatments. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $35M | 2021-06-23 | [ LEAD ] |
Atsena Therapeutics Atsena Therapeutics develops gene therapies for inherited retinal diseases, targeting conditions like X-linked retinoschisis and Leber congenital amaurosis. | Series A Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $55M | 2020-12-16 | [ PART ] |
Nouscom A clinical-stage, cancer interception focused biotech developing next-generation immunotherapies | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $48.7M | 2017-11-06 | [ LEAD ] |